De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Status:
Not yet recruiting
Trial end date:
2025-07-15
Target enrollment:
Participant gender:
Summary
This is an open-label phase 2 study designed to explore the efficacy and safety of low-dose
PTCy-ruxolitinib GVHD prophylaxis in older adults undergoing allogeneic HCT with a matched
sibling or unrelated donor with a peripheral blood stem cell graft.